Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not.

INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight-based dosing regimen. Recently, a report cited fixed-dos... View More